US News Releases

October 2022

October 5, 2022 10/5/2022 U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

September 2022

September 14, 2022 9/14/2022 Takeda Launches CDPATH™

June 2022

June 22, 2022 6/22/2022 Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

April 2022

April 18, 2022 4/18/2022 Takedas TAKHZYRO Prefilled Syringe Now Available for People With HAE Ages 12 Years and Older in the United States

February 2022

February 9, 2022 2/9/2022 Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO®

January 2022

January 31, 2022 1/31/2022 FDA Approves Prophylactic Treatment with VONVENDI®

December 2021

December 21, 2021 12/21/2021 Takeda Receives Complete Response Letter from the US FDA for TAK-721

December 13, 2021 12/13/2021 Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021